Double Bond Pharmaceutical International ABNGM: DBP.B

DBP.B: Revenue and net loss improved, with strong project progress and a major rights issue launched

· Issued by Double Bond Pharmaceutical International AB

Revenue and net results improved significantly year-over-year, driven by progress in key projects and new partnership opportunities. A major rights issue was launched, and the company is accelerating development of its pipeline, especially S1053 and SA033.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Double Bond Pharmaceutical International AB on 6ix

Story so far

Earlier from Double Bond Pharmaceutical International

Later from Double Bond Pharmaceutical International

All Double Bond Pharmaceutical International news releases